USC.edu
Are You a Patient?

John M. Ringman, MD, MS

Professor of Clinical Neurology

Helene and Lou Galen Endowed Professorship in Neurology

Image of John M. Ringman, MD, MS
Is this your profile? Click to edit
Email [email protected]
CTSI Profile

Research Funding

  • Validation of Imaging and Blood-based Small Vessel VCID Biomarkers in Multiethnic Population
    NIH · U01NS100614 · Sep 30, 2021 – Jul 31, 2026 · Role: Co-Principal Investigator
  • Phenotype and Genotype of Autosomal Dominant Alzheimer's Disease in Jalisco, Mexico
    NIH · R01AG069013 · Sep 15, 2020 – May 31, 2025 · Role: Principal Investigator
  • Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimer?s Disease
    NIH · R01AG062007 · Feb 15, 2019 – Nov 30, 2024 · Role: Principal Investigator
  • Validation of Imaging and Blood-based Small Vessel VCID Biomarkers in Multiethnic Population
    NIH · UF1NS100614 · Sep 30, 2016 – Jul 31, 2023 · Role: Co-Principal Investigator
  • Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel Disease
    NIH · UH3NS100614 · Sep 30, 2016 – Jul 31, 2021 · Role: Co-Principal Investigator
  • Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel Disease
    NIH · UH2NS100614 · Sep 30, 2016 – Jul 31, 2018 · Role: Co-Principal Investigator
  • The structural and functional connectome across Alzheimer's disease subtypes
    NIH · U01AG051218 · Sep 30, 2015 – Jun 30, 2021 · Role: Principal Investigator
  • Establishing Infrastructure for Prevention of familial AD in Mexico
    NIH · R21TW009787 · Sep 1, 2013 – Apr 30, 2018 · Role: Principal Investigator
  • FMRI in Pre-Symptomatic PS1-related Alzheimer's Disease
    NIH · K08AG022228 · Aug 1, 2003 – Jul 31, 2007 · Role: Principal Investigator
  • UCLA Alzheimer's Disease Research Center
    NIH · P50AG016570 · Apr 5, 1999 – Mar 31, 2016 · Role: Co-Principal Investigator

Publications

  • The association between white matter hyperintensities and amyloid and tau deposition. Neuroimage Clin. 2023; 38:103383.. View in PubMed
  • Decreased functional connectivity is associated with increased levels of Cerebral Spinal Fluid soluble-PDGFRβ, a marker of blood brain barrier breakdown, in older adults. Res Sq. 2023 Mar 07.. View in PubMed
  • Characterization of spastic paraplegia in a family with a novel PSEN1 mutation. Brain Commun. 2023; 5(2):fcad030.. View in PubMed
  • Retinal pathological features and proteome signatures of Alzheimer’s disease. Acta Neuropathol. 2023 04; 145(4):409-438.. View in PubMed
  • FMRI Complexity Correlates with Tau-PET and Cognitive Decline in Late-Onset and Autosomal Dominant Alzheimer’s Disease. J Alzheimers Dis. 2023; 95(2):437-451.. View in PubMed
  • First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease: the Dominantly Inherited Alzheimer’s Network Study. J Neurol Neurosurg Psychiatry. 2023 05; 94(5):403-405.. View in PubMed
  • Attitudes about involvement in hypothetical clinical trial protocols in Mexican and Mexican-American at risk for autosomal dominant Alzheimer’s disease. Alzheimers Res Ther. 2022 11 15; 14(1):173.. View in PubMed
  • Autosomal dominant and sporadic late onset Alzheimer’s disease share a common in vivo pathophysiology. Brain. 2022 10 21; 145(10):3594-3607.. View in PubMed
  • Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Ann Neurol. 2022 11; 92(5):729-744.. View in PubMed
  • Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials. Front Aging Neurosci. 2022; 14:883131.. View in PubMed

Similar People